Literature DB >> 17014406

Integrating complementary therapies into mainstream cancer care: which way forward?

Monica C Robotin1, Andrew G Penman.   

Abstract

Although viewed with scepticism by the medical and scientific community, complementary and alternative medicine (CAM) is being used by about 50% of Australians. Integrative medicine is a holistic approach to cancer care, with some CAM of proven effectiveness being used as adjuvants to conventional medical treatments. However, there is little evidence of a systematic process of evaluation or dialogue between mainstream cancer medicine and CAM providers in Australia. Collaboration, guidance and support for relevant research in this area are needed. The key elements of a process of furthering integrative medicine include improving knowledge about CAM; addressing uncertainties about CAM efficacy and safety; improving communication about CAM between medical practitioners and patients, and between medical practitioners and CAM practitioners; introducing regulatory frameworks and credentialing of CAM practitioners; and addressing ethical issues.

Entities:  

Mesh:

Year:  2006        PMID: 17014406

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  14 in total

1.  Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients.

Authors:  Darren Hunter; Richard Oates; Janet Gawthrop; Michelle Bishop; Suki Gill
Journal:  Support Care Cancer       Date:  2014-01-19       Impact factor: 3.603

2.  Guidance for establishing an integrative oncology service in the Australian healthcare setting-a discussion paper.

Authors:  Suzanne J Grant; Jennifer Hunter; Alan Bensoussan; Geoff P Delaney
Journal:  Support Care Cancer       Date:  2017-09-01       Impact factor: 3.603

3.  Classification of CAM use and its correlates in patients with early-stage breast cancer.

Authors:  Juliann Saquib; Lisa Madlensky; Sheila Kealey; Nazmus Saquib; Loki Natarajan; Vicky A Newman; Ruth E Patterson; John P Pierce
Journal:  Integr Cancer Ther       Date:  2011-03-07       Impact factor: 3.279

4.  Trick or treat? Australian newspaper portrayal of complementary and alternative medicine for the treatment of cancer.

Authors:  Reegan Mercurio; Jaklin Ardath Eliott
Journal:  Support Care Cancer       Date:  2009-11-27       Impact factor: 3.603

5.  Acknowledging the relevance of cognitive changes in cancer patients: perspectives of oncology practitioners in Asia.

Authors:  Yin Ting Cheung; Maung Shwe; Earl Hsien Jie Tan; Wai Keung Chui; Raymond Ng; Alexandre Chan
Journal:  J Cancer Surviv       Date:  2013-02-08       Impact factor: 4.442

6.  Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer.

Authors:  Juliann Saquib; Barbara A Parker; Loki Natarajan; Lisa Madlensky; Nazmus Saquib; Ruth E Patterson; Vicky A Newman; John P Pierce
Journal:  Complement Ther Med       Date:  2012-04-27       Impact factor: 2.446

7.  Human Universal Energy Improved Health-related Quality of Life Outcomes 1 Month After External Beam Radiotherapy for Early-stage Breast Cancer.

Authors:  Josef-Binh Nguyen; Eric Yeoh; Sonya Stephens; Ivan Iankov
Journal:  Integr Med (Encinitas)       Date:  2018-04

8.  Developing policy for integrating biomedicine and traditional chinese medical practice using focus groups and the delphi technique.

Authors:  Vincent C H Chung; Polly H X Ma; Chun Hong Lau; Sian M Griffiths
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-10       Impact factor: 2.629

9.  The use of Complementary and Alternative Medicine by cancer patients.

Authors:  Mariama Adams; Andrew Paul Jewell
Journal:  Int Semin Surg Oncol       Date:  2007-04-30

10.  Australian integrative oncology services: a mixed-method study exploring the views of cancer survivors.

Authors:  Jennifer Hunter; Jane Ussher; Chloe Parton; Andrew Kellett; Caroline Smith; Geoff Delaney; Eleanor Oyston
Journal:  BMC Complement Altern Med       Date:  2018-05-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.